About: Tigecycline Therapy for Multi-drug-Resistant Pseudomonas aeruginosa Sepsis Associated with Multi-organ Failure in an Infant with Persistent Arterial Duct. Case Report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tigecycline Therapy for Multi-drug-Resistant Pseudomonas aeruginosa Sepsis Associated with Multi-organ Failure in an Infant with Persistent Arterial Duct. Case Report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Tigecycline Therapy for Multi-drug-Resistant Pseudomonas aeruginosa Sepsis Associated with Multi-organ Failure in an Infant with Persistent Arterial Duct. Case Report
Creator	Kovacikova, Lubica Krasnanova, Veronika
Source	PMC
abstract	Sepsis is the leading cause of death in infants and children worldwide. The growing drug resistance in nosocomial gram-negative bacteria has resulted in treatment challenges. One of the most common multi-drug-resistant bacteria is Pseudomonas aeruginosa. Resistance to antibiotics used in Pseudomonas aeruginosa infections limits the therapeutic options. We present a tigecycline administration in a 5-month-old infant with patent arterial duct, heart failure, and respiratory failure due to respiratory syncytial virus bronchiolitis with subsequent respiratory distress syndrome and severe sepsis caused by multi-drug-resistant Pseudomonas aeruginosa. Despite combined antibiotic therapy with meropenem, amikacin, and colistin, inflammatory markers increased. Because of life-threatening condition, tigecycline was added to the therapy and was administered intravenously twice daily. Within 48 h, inflammatory markers started to decrease and tigecycline therapy continued for 13 days without adverse effects. Tigecycline used in combination with other antibiotics might be a valuable therapeutic approach in the management of multi-drug-resistant bacteria infections in pediatric patients when conventional antibiotics have failed. Further studies are needed to evaluate the efficacy and safety of tigecycline administration in critically ill pediatric patients.
has issue date	2020-07-13(xsd:dateTime)
bibo:doi	10.1007/s42399-020-00395-w
has license	no-cc
sha1sum (hex)	75305019828437a9ee804d9ca8980741c3ce0d00
schema:url	https://doi.org/10.1007/s42399-020-00395-w
resource representing a document's title	Tigecycline Therapy for Multi-drug-Resistant Pseudomonas aeruginosa Sepsis Associated with Multi-organ Failure in an Infant with Persistent Arterial Duct. Case Report
has PubMed Central identifier	PMC7357261
schema:publication	SN Compr Clin Med
resource representing a document's body	covid:75305019828437a9ee804d9ca8980741c3ce0d00#body_text
is schema:about of	named entity 'patients' named entity 'evaluate' named entity 'Pseudomonas' named entity 'bacteria' named entity 'patent' named entity 'critically ill' named entity 'intravenously' named entity 'therapy' named entity 'ADVERSE EFFECTS' named entity 'RESISTANT' named entity 'PSEUDOMONAS AERUGINOSA' named entity 'CHILDREN' named entity 'STARTED' named entity 'tigecycline' named entity 'Resistance' named entity 'tigecycline' named entity 'limits' named entity 'therapeutic' named entity 'duct' named entity 'management' named entity 'leading' named entity 'multi-drug-resistant' named entity 'inflammatory markers' named entity 'administered intravenously' named entity 'tigecycline' named entity 'gram-negative bacteria' named entity 'meropenem' named entity 'critically ill pediatric patients' named entity 'multi-drug-resistant' named entity 'Tigecycline' named entity 'respiratory syncytial virus' named entity 'Pseudomonas aeruginosa infections' named entity 'Case Report' named entity 'common' named entity 'days' named entity 'antibiotics' named entity 'Organ dysfunction' named entity 'intensive care unit' named entity 'pediatric intensive care unit' named entity 'antibiotic' named entity 'macrolide' named entity 'nosocomial' named entity 'Tigecycline' named entity 'infectious agent' named entity 'monobactams' named entity 'combination therapy' named entity 'sepsis' named entity 'antibiotics' named entity 'beta-lactamase' named entity 'adverse effects' named entity 'antibiotics' named entity 'cardiac output' named entity 'inotropic' named entity 'gram-negative' named entity 'antibiotic' named entity 'meropenem' named entity 'respiratory failure' named entity 'Pseudomonas aeruginosa' named entity 'critically ill' named entity 'polymyxins' named entity 'bacterial resistance' named entity 'immunocompromised' named entity 'patent' named entity 'Tigecycline' named entity 'carbapenem' named entity 'colistin' named entity 'sepsis' named entity 'Severe sepsis' named entity 'morbidity' named entity 'multi-organ failure' named entity 'amikacin' named entity 'amikacin' named entity 'antibiotic' named entity 'sepsis' named entity 'tigecycline' named entity 'meropenem' named entity 'upper respiratory tract' named entity 'Pseudomonas aeruginosa' named entity 'bacteria' named entity 'tigecycline' named entity 'cholestasis' named entity 'Microbial'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software